Precision Oncology News
@preconcnews.bsky.social
This feed shares top stories covering the application of genomic sequencing and other biomarker-driven approaches to guide cancer treatment. Read the latest news at https://www.precisionmedicineonline.com/cancer
In a large analysis presented at ASH's annual meeting, researchers reported that patients' MRD status after intensive chemo can predict their survival.
MRD Shows Potential as Surrogate Endpoint for Expediting AML Treatment Trials
www.precisionmedicineonline.com
December 7, 2025 at 2:22 PM
In a large analysis presented at ASH's annual meeting, researchers reported that patients' MRD status after intensive chemo can predict their survival.
One study found frail patients tend to have worse survival outcomes on the therapy, but another challenged the idea that toxicity risk increases at higher doses.
At ASH, Studies Look at Carvykti Toxicity Among Frail Multiple Myeloma Patients, Differing Doses
www.precisionmedicineonline.com
December 7, 2025 at 2:18 AM
One study found frail patients tend to have worse survival outcomes on the therapy, but another challenged the idea that toxicity risk increases at higher doses.
The results mark a setback for the hypothesis that drugs like semaglutide could provide a neuroprotective effect for patients with beta-amyloid plaque.
Novo Nordisk's GLP-1 Drug Fails to Slow Cognitive Decline in Phase III Alzheimer's Trials
www.precisionmedicineonline.com
December 5, 2025 at 9:58 PM
The results mark a setback for the hypothesis that drugs like semaglutide could provide a neuroprotective effect for patients with beta-amyloid plaque.
Trontinemab, designed to reach the brain better than gantenerumab, led to amyloid negativity in 92 percent of patients at the highest dose in a Phase Ib/IIa trial.
Roche Optimistic Over New Formulation of Shelved Alzheimer's Drug After Seeing Anti-Amyloid Activity
www.precisionmedicineonline.com
December 3, 2025 at 4:08 PM
Trontinemab, designed to reach the brain better than gantenerumab, led to amyloid negativity in 92 percent of patients at the highest dose in a Phase Ib/IIa trial.
The nonprofit is focused on access to precision medicine testing and treatment for former Special Operations Forces personnel with cancer.
Soteria Aims to Improve Patient Navigation, Data Availability for Veterans With Cancer
www.precisionmedicineonline.com
November 28, 2025 at 4:08 AM
The nonprofit is focused on access to precision medicine testing and treatment for former Special Operations Forces personnel with cancer.
A study using IHC reference slides found variability among labs in the lower limit of HER2 expression they can detect, even when the labs used the same test and reagents.
IHC Reference Standards Aim to Help Labs Measure Low HER2 Expression to Guide Enhertu Treatment
www.precisionmedicineonline.com
November 27, 2025 at 4:03 PM
A study using IHC reference slides found variability among labs in the lower limit of HER2 expression they can detect, even when the labs used the same test and reagents.
With $1.6 million from CPRIT, investigators are testing an endogenous T-cell therapy that has certain advantages over CAR T-cell therapy.
MD Anderson Researchers Secure Grant to Test Cell Therapy in Melanoma Patients With Brain Metastasis
www.precisionmedicineonline.com
November 27, 2025 at 4:02 AM
With $1.6 million from CPRIT, investigators are testing an endogenous T-cell therapy that has certain advantages over CAR T-cell therapy.
The nonprofit is focused on access to precision medicine testing and treatment for former Special Operations Forces personnel with cancer.
Soteria Aims to Improve Patient Navigation, Data Availability for Veterans With Cancer
www.precisionmedicineonline.com
November 27, 2025 at 1:19 AM
The nonprofit is focused on access to precision medicine testing and treatment for former Special Operations Forces personnel with cancer.
Abbott CEO Robert Ford called cancer testing a "critically important market" that the firm has made a priority to move into.
Abbott Launches Into Cancer Testing Space, Doubling its Dx Total Addressable Market With Exact Sciences Buy
www.precisionmedicineonline.com
November 26, 2025 at 5:08 PM
Abbott CEO Robert Ford called cancer testing a "critically important market" that the firm has made a priority to move into.
A study using IHC reference slides found variability among labs in the lower limit of HER2 expression they can detect, even when the labs used the same test and reagents.
IHC Reference Standards Aim to Help Labs Measure Low HER2 Expression to Guide Enhertu Treatment
www.precisionmedicineonline.com
November 26, 2025 at 5:02 AM
A study using IHC reference slides found variability among labs in the lower limit of HER2 expression they can detect, even when the labs used the same test and reagents.
With $1.6 million from CPRIT, investigators are testing an endogenous T-cell therapy that has certain advantages over CAR T-cell therapy.
MD Anderson Researchers Secure Grant to Test Cell Therapy in Melanoma Patients With Brain Metastasis
www.precisionmedicineonline.com
November 26, 2025 at 2:56 AM
With $1.6 million from CPRIT, investigators are testing an endogenous T-cell therapy that has certain advantages over CAR T-cell therapy.
Doctors can use the test, developed by Endeavor Health in collaboration with GenomicMD, to direct more aggressive treatment to patients sooner.
Endeavor Health Deploys Polygenic Risk Score to Flag Hidden Heart Attack Risks
www.precisionmedicineonline.com
November 26, 2025 at 12:49 AM
Doctors can use the test, developed by Endeavor Health in collaboration with GenomicMD, to direct more aggressive treatment to patients sooner.
From 2017 until Oct. 1, 2025, sponsors have submitted around 50 INDs seeking to begin clinical testing of individualized antisense oligonucleotides.
FDA Braces for Growing Demand to Test Individualized, Mutation-Specific Therapies
www.precisionmedicineonline.com
November 25, 2025 at 8:37 PM
From 2017 until Oct. 1, 2025, sponsors have submitted around 50 INDs seeking to begin clinical testing of individualized antisense oligonucleotides.
Abbott CEO Robert Ford called cancer testing a "critically important market" that the firm has made a priority to move into.
Abbott Launches Into Cancer Testing Space, Doubling its Dx Total Addressable Market With Exact Sciences Buy
www.precisionmedicineonline.com
November 25, 2025 at 5:03 PM
Abbott CEO Robert Ford called cancer testing a "critically important market" that the firm has made a priority to move into.
Following guidance from the FDA prioritizing preclinical alternatives to mouse models, some academic and community cancer centers are setting up organoid cores.
Organoid Labs at Cancer Centers Hope to Bring Precision Therapy Research Closer to Patients
www.precisionmedicineonline.com
November 25, 2025 at 12:29 AM
Following guidance from the FDA prioritizing preclinical alternatives to mouse models, some academic and community cancer centers are setting up organoid cores.
From 2017 until Oct. 1, 2025, sponsors have submitted around 50 INDs seeking to begin clinical testing of individualized antisense oligonucleotides.
FDA Braces for Growing Demand to Test Individualized, Mutation-Specific Therapies
www.precisionmedicineonline.com
November 24, 2025 at 4:33 PM
From 2017 until Oct. 1, 2025, sponsors have submitted around 50 INDs seeking to begin clinical testing of individualized antisense oligonucleotides.
An investigator-developed drug has shown preclinical efficacy and is worth testing in clinical trials in aggressive breast and other cancers, experts say.
UCSD Researchers Want Pharma to Take Another Chance at FZD7-Targeted ADC
www.precisionmedicineonline.com
November 20, 2025 at 9:46 PM
An investigator-developed drug has shown preclinical efficacy and is worth testing in clinical trials in aggressive breast and other cancers, experts say.
Exact Sciences shareholders will receive $105 per common share as part of the deal, which is expected to close in the second quarter of 2026.
Abbott to Acquire Exact Sciences for $23B
www.precisionmedicineonline.com
November 20, 2025 at 4:24 PM
Exact Sciences shareholders will receive $105 per common share as part of the deal, which is expected to close in the second quarter of 2026.
Investigators at Boston institutions believe the regimen could target immunosuppressive lipid macrophages and improve treatment outcomes.
SPORE-Funded Work to Test if CSF-1R Inhibitor Overcomes PARP Inhibitor Resistance in Breast Cancer
www.precisionmedicineonline.com
November 15, 2025 at 1:55 AM
Investigators at Boston institutions believe the regimen could target immunosuppressive lipid macrophages and improve treatment outcomes.
The draft guidelines include language on reporting biomarkers predicting therapy response or resistance, liquid biopsy, and mutational signatures like TMB, MSI, and HRD.
AMP Group Unveils New Draft Guidelines for Interpreting, Reporting Cancer Sequencing Variants
www.precisionmedicineonline.com
November 14, 2025 at 9:56 PM
The draft guidelines include language on reporting biomarkers predicting therapy response or resistance, liquid biopsy, and mutational signatures like TMB, MSI, and HRD.
A sponsor will have to demonstrate success with "with several consecutive patients with different bespoke therapies" to receive an approval.
FDA Introduces 'Plausible Mechanism Pathway' to Spur Personalized Therapy Development
www.precisionmedicineonline.com
November 14, 2025 at 5:03 PM
A sponsor will have to demonstrate success with "with several consecutive patients with different bespoke therapies" to receive an approval.
A sponsor will have to demonstrate success with "with several consecutive patients with different bespoke therapies" to receive an approval.
FDA Introduces 'Plausible Mechanism Pathway' to Spur Personalized Therapy Development
www.precisionmedicineonline.com
November 13, 2025 at 4:31 PM
A sponsor will have to demonstrate success with "with several consecutive patients with different bespoke therapies" to receive an approval.
CTX310 showed promising safety and efficacy in a small Phase I trial, according to data presented at the American Heart Association's conference.
CRISPR Therapeutics' Gene-Editing Drug Cuts LDL Cholesterol, Triglycerides in Early Human Trial
www.precisionmedicineonline.com
November 11, 2025 at 1:11 AM
CTX310 showed promising safety and efficacy in a small Phase I trial, according to data presented at the American Heart Association's conference.
At its annual meeting, the society discussed progress it has made in pushing ahead the Access to Genetic Counselor Services Act and other policy priorities.
NSGC Navigating Government Shutdown, Midterms in Continued Push for Medicare Recognition
www.precisionmedicineonline.com
November 10, 2025 at 11:07 PM
At its annual meeting, the society discussed progress it has made in pushing ahead the Access to Genetic Counselor Services Act and other policy priorities.
At its annual meeting, the society discussed progress it has made in pushing ahead the Access to Genetic Counselor Services Act and other policy priorities.
NSGC Navigating Government Shutdown, Midterms in Continued Push for Medicare Recognition
www.precisionmedicineonline.com
November 10, 2025 at 8:08 PM
At its annual meeting, the society discussed progress it has made in pushing ahead the Access to Genetic Counselor Services Act and other policy priorities.